Invitae announced a partnership with BridgeBio Pharma, Inc. designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. The agreement expands upon the longstanding partnership between the two companies to combine the strengths of BridgeBio's deep expertise in rare disease research and development of therapeutics, and Invitae's rare disease enriched dataset and analytical capabilities.

Invitae has provided clinical testing for more than 4 million patients, generating an extensive dataset that is uniquely positioned to deepen insights on patients with genetic-driven disease. Access to large genetic and clinical datasets are needed to advance research and discover novel drug targets and are often hard to find for researchers. Together Invitae and BridgeBio will translate genetic and phenotypic data into insights to improve therapeutic discovery and design for patients with rare disease.

Invitae will analyze longitudinal medical phenotypes in linked genetic and clinical datasets, in order to understand the burden of disease in a real-world setting. Harnessing BridgeBio's disease expertise, Invitae will leverage AI-based phenotypic clustering to identify subgroups of patients based on their genetic and phenotypic profiles. Invitae will also conduct association testing to identify potential genetic modifiers of disease phenotype, severity, onset and progression.